Description
Springer Hypertrophic Cardiomyopathy The Therapeutic Role of Calcium Antagonists 1st Editon 2011 Softbound by M. Kaltenbach, S.E. Epstein
First described in 1907 by Schicke but recognized as a clinical entity only as recently as 1958, when Teare published the pathologic findings in patients with hypertrophic cardiomyopathy (HeM), an explosion of knowledge about this fascinating disease has occurred, which has caused a profound evolution of our understanding of its broad pathophysiologic and clinical spectrum. Progress has been particularly rapid in the past few years when M-mode echocardiography, and more recently 2-dimen sional echocardiography have been applied to the study ofHCM. In addition to new insights as to what the disease is, there has been enormous progress concerning its treatment, with the application of beta-adrenergic blocking agents and surgical relief of left ventricular outflow tract obstruction. Although these approaches have led to great strides in the symptomatic control of the disease, many patients' symptoms have remained refactory to medical and surgical therapy. Most discouragingly, sudden death still occurs, even in patients on large doses of beta-blocking agents and in patients who have had surgical relief of left ventricular outflow tract obstruction. Clinical and Anatomical Characterization of Hypertrophic Cardiomyopathy.- Synopsis.- Hypertrophic Cardiomyopathy: An Overview.- Echocardiographic Identification of Patterns of Left Ventricular Hypertrophy in Hypertrophic Cardiomyopathy.- Distribution and Significance of Cardiac Muscle Cell Disorganization in the Left Ventricle of Patients with Hypertrophic Cardiomyopathy: Evidence of a Diffuse Cardiomyopathic Process.- Left Ventricular Biopsy in Hypertrophic Cardiomyopathy: Light and Electron Microscopic Evaluations.- Cardiomyopathy in Animals and Therapeutic Interventions.- Synopsis.- Spontaneously Occurring Hypertrophic Cardiomyopathy in Dogs and Cats: A Potential Animal Model of a Human Disease.- Cardiac Effects of Nerve Growth Factor in Dogs.- Prevention of Myocardial Cell Necrosis in the Syrian Hamster — Results of Long-Term Treatment.- Prevention by Verapamil of Isoproterenol-Induced Hypertrophic Cardiomyopathy in Rats.- Effects of Acute Administration of Verapamil in Patients with Hypertrophic Cardiomyopathy.- Synopsis.- Acute Hemodynamic Effects of Verapamil in Hypertrophic Cardiomyopathy.- Hemodynamics and Contractility After Oral, Intravenous, and Intracoronary Application of Calcium Antagonists.- Effect of Verapamil on Left Ventricular Isovolumic Relaxation Time and Regional Left Ventricular Filling in Hypertrophic Cardiomyopathy.- Treatment of Hypertrophic Cardiomyopathy with Verapamil.- Synopsis.- Verapamil Treatment of Hypertrophic Cardiomyopathy.- Volume Parameters of the Heart During Long-Term Verapamil Treatment in Patients with Hypertrophic Cardiomyopathy.- Long-Term Clinical Effects of Verapamil in Patients with Hypertrophic Cardiomyopathy.- Effects of Verapamil on Ventricular Wall Thickness of Patients with Hypertrophic Cardiomyopathy.- Long-Term Verapamil Treatment in Patients with Hypertrophic Nonobstructive Cardiomyopathy.- Verapamil: Its Potential for Causing Serious Complications in Patients with Hypertrophic Cardiomyopathy.- Long-Term Results of Different Therapeutic Interventions in Comparison with Verapamil.- Synopsis.- Efficacy of Operation for Obstructive Hypertrophic Cardiomyopathy: A 20-Year Experience with Ventricular Septal Myotomy and Myectomy.- Functional Results in Medically and Surgically Treated Patients with Hypertrophic Obstructive Cardiomyopathy.- Long-Term Treatment of Hypertrophic Cardiomyopathy with Verapamil or Propranolol. Preliminary Results of a Multicenter Study.- Effects of Different Calcium Blockers and Implications Regarding Therapy of Hypertrophic Cardiomyopathy.- Synopsis.- The Antianginal Efficacy of Seven Different Calcium Antagonists.- Differentiation of Calcium-Antagonistic Drugs with Respect to Their Myocardial Effects.- The Concept of Calcium Antagonist Therapy in Cardiac Hypertrophy. Different Calcium Antagonists with Respect to Therapeutic Efficacy in Hypertrophic Cardiomyopathy. Combined Therapy with Calcium Antagonists and Other Drugs?.- Clinical Pharmacology of Verapamil in Hypertrophic Cardiomyopathy.- Synopsis.- Pharmacokinetics, Bioavailability, and ECG Response of Verapamil in Man.- Verapamil Plasma Concentrations and Indices of Heart Size in Hypertrophic Obstructive Cardiomyopathy — Evidence for the Existence of a Therapeutic Range.- Plasma Verapamil Levels in Patients with Hypertrophic Cardiomyopathy: Interpatient Variability and Clinical Usefulness.- Correlation of Verapamil Plasma Levels with Electrocardiographic and Hemodynamic Effects.